Otitis Media Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
![](/report_cover/2671/otitis-media-drugs-in-development-by-stages-target-moa-roa-molecule-type-n-key-players-2022-update_en.gif)
Otitis Media Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
SUMMARY
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Otitis Media - Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update, provides an overview of the Otitis Media (Ear Nose Throat Disorders) pipeline landscape.
Otitis media (OM) is any inflammation of the middle ear, the air-filled space behind the eardrum that contains the tiny vibrating bones of the ear. Symptoms include ear pain, difficulty sleeping, loss of balance, fever, headache and loss of appetite. Risk factors include age, seasonal factors and exposure to tobacco smoke or high levels of air pollution. Treatment includes antibiotics and antipyrine.
REPORT HIGHLIGHTS
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Otitis Media - Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update, provides comprehensive information on the therapeutics under development for Otitis Media (Ear Nose Throat Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Otitis Media (Ear Nose Throat Disorders) pipeline guide also reviews of key players involved in therapeutic development for Otitis Media and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Preclinical and Discovery stages are 1, 4, 1, 15 and 2 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.
Otitis Media (Ear Nose Throat Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
SCOPE
SUMMARY
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Otitis Media - Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update, provides an overview of the Otitis Media (Ear Nose Throat Disorders) pipeline landscape.
Otitis media (OM) is any inflammation of the middle ear, the air-filled space behind the eardrum that contains the tiny vibrating bones of the ear. Symptoms include ear pain, difficulty sleeping, loss of balance, fever, headache and loss of appetite. Risk factors include age, seasonal factors and exposure to tobacco smoke or high levels of air pollution. Treatment includes antibiotics and antipyrine.
REPORT HIGHLIGHTS
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Otitis Media - Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update, provides comprehensive information on the therapeutics under development for Otitis Media (Ear Nose Throat Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Otitis Media (Ear Nose Throat Disorders) pipeline guide also reviews of key players involved in therapeutic development for Otitis Media and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Preclinical and Discovery stages are 1, 4, 1, 15 and 2 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.
Otitis Media (Ear Nose Throat Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
SCOPE
- The pipeline guide provides a snapshot of the global therapeutic landscape of Otitis Media (Ear Nose Throat Disorders).
- The pipeline guide reviews pipeline therapeutics for Otitis Media (Ear Nose Throat Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Otitis Media (Ear Nose Throat Disorders) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Otitis Media (Ear Nose Throat Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Otitis Media (Ear Nose Throat Disorders)
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Otitis Media (Ear Nose Throat Disorders).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Otitis Media (Ear Nose Throat Disorders) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Introduction
Global Markets Direct Report Coverage
Otitis Media - Overview
Otitis Media - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Otitis Media - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Otitis Media - Companies Involved in Therapeutics Development
Blue Water Vaccines Inc
Ceolia Pharma Co Ltd
Clarametyx Biosciences Inc
Earnano LLC
Furen Pharmaceutical Group Co Ltd
Hunan Sanqing Pharmaceutical Co Ltd
Inventprise LLC
Laboratorios Salvat SA
Maxwell Biosciences Inc
Merck & Co Inc
MerLion Pharmaceuticals Pte Ltd
MyX Therapeutics Inc
NTC srl
O-Ray Pharma Inc
Olymvax Biopharmaceuticals Inc
ProclaRx LLC
Vaxcyte Inc
Vyome Therapeutics Inc
Otitis Media - Drug Profiles
(ciprofloxacin hydrochloride + fluocinolone acetonide) - Drug Profile
Product Description
Mechanism Of Action
History of Events
aspoxicillin - Drug Profile
Product Description
Mechanism Of Action
BWV-201 - Drug Profile
Product Description
Mechanism Of Action
History of Events
CMTX-200 - Drug Profile
Product Description
Mechanism Of Action
CMTX-301 - Drug Profile
Product Description
Mechanism Of Action
Drug for Otitis Media - Drug Profile
Product Description
Mechanism Of Action
Drugs for Otitis Media - Drug Profile
Product Description
Mechanism Of Action
ENT-103 - Drug Profile
Product Description
Mechanism Of Action
History of Events
finafloxacin - Drug Profile
Product Description
Mechanism Of Action
History of Events
IVT-25 - Drug Profile
Product Description
Mechanism Of Action
NTC-011 - Drug Profile
Product Description
Mechanism Of Action
OR-404IT - Drug Profile
Product Description
Mechanism Of Action
History of Events
PCL-1440 - Drug Profile
Product Description
Mechanism Of Action
History of Events
pneumococcal (13-valent) vaccine - Drug Profile
Product Description
Mechanism Of Action
pneumococcal (23-valent) vaccine - Drug Profile
Product Description
Mechanism Of Action
pneumococcal polysaccharide [15-valent] vaccine - Drug Profile
Product Description
Mechanism Of Action
History of Events
Small Molecules for Chronic Suppurative Otitis Media (CSOM) - Drug Profile
Product Description
Mechanism Of Action
History of Events
solithromycin - Drug Profile
Product Description
Mechanism Of Action
History of Events
tebipenem pivoxil - Drug Profile
Product Description
Mechanism Of Action
Vaccine for Otitis Media - Drug Profile
Product Description
Mechanism Of Action
VAX-24 - Drug Profile
Product Description
Mechanism Of Action
VAX-XP - Drug Profile
Product Description
Mechanism Of Action
VT-1917 - Drug Profile
Product Description
Mechanism Of Action
Otitis Media - Dormant Projects
Otitis Media - Discontinued Products
Otitis Media - Product Development Milestones
Featured News & Press Releases
Dec 20, 2021: Clarametyx Biosciences awarded $3.15 million grant from NIH to advance a broad-spectrum vaccine technology for bacterial infections
Oct 04, 2021: Lee’s Pharmaceutical Holdings: Voluntary announcement - Update on the commercialisation and research and development of Cetraxal Plus of the group
Sep 01, 2021: NanoCarrier : Accomplishment of primary endpoint in phase III clinical study of ENT103
May 31, 2021: NanoCarrier : Completion of patient enrollment for phase III trial with ENT103
Jan 13, 2021: Lee’s Pharmaceutical Holdings: Voluntary announcement update on an investigational ear drug product
Jun 02, 2017: Eight Presentations at ASM Microbe Include Late Breaker From Cempra’s Phase 3 Fusidic Acid Study and Solithromycin Data on Gonorrhea and Otitis Media
May 18, 2017: Pediapharm Announces the Commercial Launch of Otixal in Canada
Dec 27, 2016: OTOVEL's trials published in JAMA
Dec 12, 2016: Pediapharm receives Health Canada approval for Otixal
Sep 29, 2014: SALVAT announces positive top-line results from two Phase III studies of its novel otic antibiotic/steroid combination solution in the treatment of AOMT with Tympanostomy tubes
May 28, 2013: Salvat Completes Enrollment Of Phase III Study For New Combination In Acute Otitis Media In Pediatric Patients With Tympanostomy Tubes
Apr 18, 2012: MerLion Initiates Phase III Clinical Program To Evaluate Finafloxacin For Treatment Of Acute Otitis Media
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
Global Markets Direct Report Coverage
Otitis Media - Overview
Otitis Media - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Otitis Media - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Otitis Media - Companies Involved in Therapeutics Development
Blue Water Vaccines Inc
Ceolia Pharma Co Ltd
Clarametyx Biosciences Inc
Earnano LLC
Furen Pharmaceutical Group Co Ltd
Hunan Sanqing Pharmaceutical Co Ltd
Inventprise LLC
Laboratorios Salvat SA
Maxwell Biosciences Inc
Merck & Co Inc
MerLion Pharmaceuticals Pte Ltd
MyX Therapeutics Inc
NTC srl
O-Ray Pharma Inc
Olymvax Biopharmaceuticals Inc
ProclaRx LLC
Vaxcyte Inc
Vyome Therapeutics Inc
Otitis Media - Drug Profiles
(ciprofloxacin hydrochloride + fluocinolone acetonide) - Drug Profile
Product Description
Mechanism Of Action
History of Events
aspoxicillin - Drug Profile
Product Description
Mechanism Of Action
BWV-201 - Drug Profile
Product Description
Mechanism Of Action
History of Events
CMTX-200 - Drug Profile
Product Description
Mechanism Of Action
CMTX-301 - Drug Profile
Product Description
Mechanism Of Action
Drug for Otitis Media - Drug Profile
Product Description
Mechanism Of Action
Drugs for Otitis Media - Drug Profile
Product Description
Mechanism Of Action
ENT-103 - Drug Profile
Product Description
Mechanism Of Action
History of Events
finafloxacin - Drug Profile
Product Description
Mechanism Of Action
History of Events
IVT-25 - Drug Profile
Product Description
Mechanism Of Action
NTC-011 - Drug Profile
Product Description
Mechanism Of Action
OR-404IT - Drug Profile
Product Description
Mechanism Of Action
History of Events
PCL-1440 - Drug Profile
Product Description
Mechanism Of Action
History of Events
pneumococcal (13-valent) vaccine - Drug Profile
Product Description
Mechanism Of Action
pneumococcal (23-valent) vaccine - Drug Profile
Product Description
Mechanism Of Action
pneumococcal polysaccharide [15-valent] vaccine - Drug Profile
Product Description
Mechanism Of Action
History of Events
Small Molecules for Chronic Suppurative Otitis Media (CSOM) - Drug Profile
Product Description
Mechanism Of Action
History of Events
solithromycin - Drug Profile
Product Description
Mechanism Of Action
History of Events
tebipenem pivoxil - Drug Profile
Product Description
Mechanism Of Action
Vaccine for Otitis Media - Drug Profile
Product Description
Mechanism Of Action
VAX-24 - Drug Profile
Product Description
Mechanism Of Action
VAX-XP - Drug Profile
Product Description
Mechanism Of Action
VT-1917 - Drug Profile
Product Description
Mechanism Of Action
Otitis Media - Dormant Projects
Otitis Media - Discontinued Products
Otitis Media - Product Development Milestones
Featured News & Press Releases
Dec 20, 2021: Clarametyx Biosciences awarded $3.15 million grant from NIH to advance a broad-spectrum vaccine technology for bacterial infections
Oct 04, 2021: Lee’s Pharmaceutical Holdings: Voluntary announcement - Update on the commercialisation and research and development of Cetraxal Plus of the group
Sep 01, 2021: NanoCarrier : Accomplishment of primary endpoint in phase III clinical study of ENT103
May 31, 2021: NanoCarrier : Completion of patient enrollment for phase III trial with ENT103
Jan 13, 2021: Lee’s Pharmaceutical Holdings: Voluntary announcement update on an investigational ear drug product
Jun 02, 2017: Eight Presentations at ASM Microbe Include Late Breaker From Cempra’s Phase 3 Fusidic Acid Study and Solithromycin Data on Gonorrhea and Otitis Media
May 18, 2017: Pediapharm Announces the Commercial Launch of Otixal in Canada
Dec 27, 2016: OTOVEL's trials published in JAMA
Dec 12, 2016: Pediapharm receives Health Canada approval for Otixal
Sep 29, 2014: SALVAT announces positive top-line results from two Phase III studies of its novel otic antibiotic/steroid combination solution in the treatment of AOMT with Tympanostomy tubes
May 28, 2013: Salvat Completes Enrollment Of Phase III Study For New Combination In Acute Otitis Media In Pediatric Patients With Tympanostomy Tubes
Apr 18, 2012: MerLion Initiates Phase III Clinical Program To Evaluate Finafloxacin For Treatment Of Acute Otitis Media
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
LIST OF TABLES
Number of Products under Development for Otitis Media, 2022
Number of Products under Development by Companies, 2022
Number of Products under Development by Universities/Institutes, 2022
Products under Development by Companies, 2022
Products under Development by Companies, 2022 (Contd..1)
Products under Development by Universities/Institutes, 2022
Number of Products by Stage and Target, 2022
Number of Products by Stage and Mechanism of Action, 2022
Number of Products by Stage and Route of Administration, 2022
Number of Products by Stage and Molecule Type, 2022
Otitis Media - Pipeline by Blue Water Vaccines Inc, 2022
Otitis Media - Pipeline by Ceolia Pharma Co Ltd, 2022
Otitis Media - Pipeline by Clarametyx Biosciences Inc, 2022
Otitis Media - Pipeline by Earnano LLC, 2022
Otitis Media - Pipeline by Furen Pharmaceutical Group Co Ltd, 2022
Otitis Media - Pipeline by Hunan Sanqing Pharmaceutical Co Ltd, 2022
Otitis Media - Pipeline by Inventprise LLC, 2022
Otitis Media - Pipeline by Laboratorios Salvat SA, 2022
Otitis Media - Pipeline by Maxwell Biosciences Inc, 2022
Otitis Media - Pipeline by Merck & Co Inc, 2022
Otitis Media - Pipeline by MerLion Pharmaceuticals Pte Ltd, 2022
Otitis Media - Pipeline by MyX Therapeutics Inc, 2022
Otitis Media - Pipeline by NTC srl, 2022
Otitis Media - Pipeline by O-Ray Pharma Inc, 2022
Otitis Media - Pipeline by Olymvax Biopharmaceuticals Inc, 2022
Otitis Media - Pipeline by ProclaRx LLC, 2022
Otitis Media - Pipeline by Vaxcyte Inc, 2022
Otitis Media - Pipeline by Vyome Therapeutics Inc, 2022
Otitis Media - Dormant Projects, 2022
Otitis Media - Discontinued Products, 2022
Number of Products under Development for Otitis Media, 2022
Number of Products under Development by Companies, 2022
Number of Products under Development by Universities/Institutes, 2022
Products under Development by Companies, 2022
Products under Development by Companies, 2022 (Contd..1)
Products under Development by Universities/Institutes, 2022
Number of Products by Stage and Target, 2022
Number of Products by Stage and Mechanism of Action, 2022
Number of Products by Stage and Route of Administration, 2022
Number of Products by Stage and Molecule Type, 2022
Otitis Media - Pipeline by Blue Water Vaccines Inc, 2022
Otitis Media - Pipeline by Ceolia Pharma Co Ltd, 2022
Otitis Media - Pipeline by Clarametyx Biosciences Inc, 2022
Otitis Media - Pipeline by Earnano LLC, 2022
Otitis Media - Pipeline by Furen Pharmaceutical Group Co Ltd, 2022
Otitis Media - Pipeline by Hunan Sanqing Pharmaceutical Co Ltd, 2022
Otitis Media - Pipeline by Inventprise LLC, 2022
Otitis Media - Pipeline by Laboratorios Salvat SA, 2022
Otitis Media - Pipeline by Maxwell Biosciences Inc, 2022
Otitis Media - Pipeline by Merck & Co Inc, 2022
Otitis Media - Pipeline by MerLion Pharmaceuticals Pte Ltd, 2022
Otitis Media - Pipeline by MyX Therapeutics Inc, 2022
Otitis Media - Pipeline by NTC srl, 2022
Otitis Media - Pipeline by O-Ray Pharma Inc, 2022
Otitis Media - Pipeline by Olymvax Biopharmaceuticals Inc, 2022
Otitis Media - Pipeline by ProclaRx LLC, 2022
Otitis Media - Pipeline by Vaxcyte Inc, 2022
Otitis Media - Pipeline by Vyome Therapeutics Inc, 2022
Otitis Media - Dormant Projects, 2022
Otitis Media - Discontinued Products, 2022
LIST OF FIGURES
Number of Products under Development for Otitis Media, 2022
Number of Products under Development by Companies, 2022
Number of Products by Targets, 2022
Number of Products by Stage and Targets, 2022
Number of Products by Mechanism of Actions, 2022
Number of Products by Stage and Mechanism of Actions, 2022
Number of Products by Routes of Administration, 2022
Number of Products by Stage and Routes of Administration, 2022
Number of Products by Molecule Types, 2022
Number of Products by Stage and Molecule Types, 2022
Number of Products under Development for Otitis Media, 2022
Number of Products under Development by Companies, 2022
Number of Products by Targets, 2022
Number of Products by Stage and Targets, 2022
Number of Products by Mechanism of Actions, 2022
Number of Products by Stage and Mechanism of Actions, 2022
Number of Products by Routes of Administration, 2022
Number of Products by Stage and Routes of Administration, 2022
Number of Products by Molecule Types, 2022
Number of Products by Stage and Molecule Types, 2022